Assessment of Serum and Tissue Tryptase Levels in Acne Vulgaris Patients

Launched by SOHAG UNIVERSITY · Nov 28, 2023

Keywords

ClinConnect Summary

This clinical trial is studying the levels of a protein called tryptase in patients with acne vulgaris, which is a common skin condition causing pimples and inflammation. The researchers believe that tryptase, produced by certain immune cells called mast cells, may play a role in how acne develops and persists. Acne affects many people, especially teenagers, and understanding its underlying mechanisms could lead to better treatments.

To participate in this study, you need to be at least 18 years old and have acne vulgaris. However, pregnant or breastfeeding women, those using hormonal contraceptives, or individuals who have used acne treatments in the past six months will not be eligible. Participants will have their blood and tissue samples tested to measure tryptase levels, which could provide valuable insights into acne. It’s important to note that the trial is not yet recruiting participants, so there will be more information available once it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients with acne vulgaris ≥ 18 years old, both male and female patients will be included.
• Exclusion Criteria:
• • Patients with the following criteria will be excluded from our study: 1- Pregnancy and breast feeding women. 2- Women on hormonal contraceptions. 3- Patients on topical/systemic treatment for AV during the last 6 months prior to the study. 4- Patients with other dermatological diseases e.g. psoriasis, vitiligo, DLE, etc. 5- Patients suffering from chronic medical illness such as; diabetes mellitus, thyroid disease, and cancer.